Developer docs
API playgroundTry for free, no card

Search company profiles

Magenta Therapeutics

Full company profile

uuid00065jo

Namestring
Magenta Therapeutics
Legal namestring
Magenta Therapeutics
Websiteurl
magentatx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Magenta Therapeutics was a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2015 to develop therapeutics based on stem cell biology. The company's focus was on conditioning regimens (antibody-drug conjugate-based approaches) and stem cell mobilization products intended to enable or improve bone marrow transplantation and gene therapy procedures. Strategic investor participation from Be The Match BioTherapies in multiple rounds signals a deliberate orientation toward the transplant and hematology clinical ecosystem. The company was publicly traded on Nasdaq under the ticker MGTA but has since been delisted, reflecting an unsuccessful commercial trajectory.

Magenta operated a pre-revenue business model typical of clinical-stage biotechs: capital was raised through successive equity financings (six rounds totaling approximately $405.9M from 2016 to 2021) and deployed into R&D and clinical development of its pipeline candidates. Investor composition evolved from early-stage venture (Atlas Venture, Third Rock Ventures, Google Ventures) through crossover and healthcare-specialist funds (Deep Track Capital, Great Point Partners, Janus Henderson, OrbiMed, TCG Crossover). There is no evidence in source materials of licensing revenue, royalties, or commercial product sales. The company's customer base in any commercial sense is therefore non-existent at the time of available data, with eventual customers presumed to be hospital transplant centers, specialty hematology practices, and gene therapy programs.

The company's go-to-market upon commercialization would have relied on the standard biotech model of either independent specialty sales targeting bone marrow transplant centers, partnership with larger pharma for commercialization, or co-promotion arrangements. Scientific founding was anchored by co-founder David Scadden, a prominent Harvard/MGH stem cell biologist. Leadership at the time of available data included chairman roles held by Alison Lawton and Michael Bonney, with Steve Mahoney serving as CFO/COO and Bastiano Sanna as COO. Reported annual operating losses were in the tens of millions of dollars, consistent with a 51-100 employee clinical development organization.

Short descriptiontext

Magenta Therapeutics was a Cambridge, MA-based clinical-stage biotechnology company founded in 2015 developing stem cell-based therapeutics, including conditioning regimens for bone marrow transplant and gene therapy. The company is now delisted from Nasdaq.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
stem cell therapeutics, hematopoietic stem cells, transplant conditioning, clinical-stage biopharmaceuticals, cell biology biologics
Industry2 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Scientific Research and Development Services5417
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics based on stem cell biology, with a focus on hematopoietic stem cell transplant conditioning and immune reset for patients with hematologic diseases and genetic disorders. The company advances biologic drug candidates intended for clinical use in transplant and immune-mediated disease settings.

Differentiator
Functional benefit
Problem solved
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Base-editing biotech with ex vivo HSC programs (e.g., for sickle cell disease). Comparable in that its therapeutic approach depends on the same transplant infrastructure and conditioning workflows Magenta targets.

TypeBroad incumbent
Description

Clinical-stage gene editing company with ex vivo HSC programs. Operates in adjacent transplant infrastructure, sharing the same conditioning and mobilization workflows Magenta seeks to improve.

TypeBroad incumbent
Description

Through its Casgevy partnership with CRISPR Therapeutics, Vertex is a major commercial player in stem cell-based gene therapy. Operates at scale in the same downstream indications Magenta's enabling platform addresses.

4bluebird bio
TypeDirect peer
Description

Gene therapy company with ex vivo lentiviral therapies (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy) that depend on conditioning regimens overlapping with Magenta's transplant-conditioning focus.

TypeBroad incumbent
Description

Commercializing Casgevy (exa-cel) for sickle cell disease and beta-thalassemia. Uses hematopoietic stem cell editing requiring conditioning, putting it in adjacent competition for the same transplant infrastructure and donor ecosystem Magenta targets.

TypeEmerging player
Description

In vivo and ex vivo CRISPR-based gene editing company with HSC-adjacent programs. Shares the broader stem cell and gene therapy ecosystem in which Magenta's conditioning platform operates.

TypeDirect peer
Description

Develops engineered hematopoietic stem cell transplants (eHSC) with engineered CD33 to enable targeted conditioning. Overlaps directly with Magenta's conditioning-plus-transplant approach and addresses the same transplant bottlenecks.

TypeDirect peer
Description

Clinical-stage biotech developing JSP191, an anti-CD117 antibody for conditioning prior to allogeneic hematopoietic stem cell transplant and gene therapy. Directly competes with Magenta's conditioning program in the same transplant-conditioning niche.

TypeDirect peer
Description

Develops Iomab-B and other targeted conditioning agents for hematopoietic stem cell transplantation. Targets the same transplant-conditioning indication as Magenta with a different modality (radioimmunotherapy).

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T company using healthy donor T cells. Adjacent because allogeneic cell therapies intersect with the same donor, mobilization, and conditioning infrastructure Magenta targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Magenta Therapeutics

Biopharmaceuticalsmagentatx.com

Magenta Therapeutics was a Cambridge, MA-based clinical-stage biotechnology company founded in 2015 developing stem cell-based therapeutics, including conditioning regimens for bone marrow transplant and gene therapy. The company is now delisted from Nasdaq.

What Magenta Therapeutics does

Magenta Therapeutics was a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2015 to develop therapeutics based on stem cell biology. The company's focus was on conditioning regimens (antibody-drug conjugate-based approaches) and stem cell mobilization products intended to enable or improve bone marrow transplantation and gene therapy procedures. Strategic investor participation from Be The Match BioTherapies in multiple rounds signals a deliberate orientation toward the transplant and hematology clinical ecosystem. The company was publicly traded on Nasdaq under the ticker MGTA but has since been delisted, reflecting an unsuccessful commercial trajectory.

Magenta operated a pre-revenue business model typical of clinical-stage biotechs: capital was raised through successive equity financings (six rounds totaling approximately $405.9M from 2016 to 2021) and deployed into R&D and clinical development of its pipeline candidates. Investor composition evolved from early-stage venture (Atlas Venture, Third Rock Ventures, Google Ventures) through crossover and healthcare-specialist funds (Deep Track Capital, Great Point Partners, Janus Henderson, OrbiMed, TCG Crossover). There is no evidence in source materials of licensing revenue, royalties, or commercial product sales. The company's customer base in any commercial sense is therefore non-existent at the time of available data, with eventual customers presumed to be hospital transplant centers, specialty hematology practices, and gene therapy programs.

The company's go-to-market upon commercialization would have relied on the standard biotech model of either independent specialty sales targeting bone marrow transplant centers, partnership with larger pharma for commercialization, or co-promotion arrangements. Scientific founding was anchored by co-founder David Scadden, a prominent Harvard/MGH stem cell biologist. Leadership at the time of available data included chairman roles held by Alison Lawton and Michael Bonney, with Steve Mahoney serving as CFO/COO and Bastiano Sanna as COO. Reported annual operating losses were in the tens of millions of dollars, consistent with a 51-100 employee clinical development organization.

Magenta Therapeutics firmographics

Firmographics
Name
Magenta Therapeutics
Legal name
Magenta Therapeutics
Website
https://magentatx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Magenta Therapeutics was a Cambridge, MA-based clinical-stage biotechnology company founded in 2015 developing stem cell-based therapeutics, including conditioning regimens for bone marrow transplant and gene therapy. The company is now delisted from Nasdaq.
Ownership category
akta.pro rank

Magenta Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Stem cell therapeutics
  • Hematopoietic stem cells
  • Transplant conditioning
  • Clinical-stage biopharmaceuticals
  • Cell biology biologics

Where Magenta Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Magenta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Magenta Therapeutics product offering

Product offering

Core offering

Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics based on stem cell biology, with a focus on hematopoietic stem cell transplant conditioning and immune reset for patients with hematologic diseases and genetic disorders. The company advances biologic drug candidates intended for clinical use in transplant and immune-mediated disease settings.

Differentiator

Problem solved

Functional benefit

Companies that use Magenta Therapeutics

Customer profile

Ideal customer profiles1 record

Magenta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Magenta Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Magenta Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Beam Therapeutics: Base-editing biotech with ex vivo HSC programs (e.g., for sickle cell disease). Comparable in that its therapeutic approach depends on the same transplant infrastructure and conditioning workflows Magenta targets.
  • Editas Medicine: Clinical-stage gene editing company with ex vivo HSC programs. Operates in adjacent transplant infrastructure, sharing the same conditioning and mobilization workflows Magenta seeks to improve.
  • Vertex Pharmaceuticals: Through its Casgevy partnership with CRISPR Therapeutics, Vertex is a major commercial player in stem cell-based gene therapy. Operates at scale in the same downstream indications Magenta's enabling platform addresses.
  • CRISPR Therapeutics: Commercializing Casgevy (exa-cel) for sickle cell disease and beta-thalassemia. Uses hematopoietic stem cell editing requiring conditioning, putting it in adjacent competition for the same transplant infrastructure and donor ecosystem Magenta targets.

Direct peers

  • bluebird bio: Gene therapy company with ex vivo lentiviral therapies (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy) that depend on conditioning regimens overlapping with Magenta's transplant-conditioning focus.
  • Vor Biopharma: Develops engineered hematopoietic stem cell transplants (eHSC) with engineered CD33 to enable targeted conditioning. Overlaps directly with Magenta's conditioning-plus-transplant approach and addresses the same transplant bottlenecks.
  • Jasper Therapeutics: Clinical-stage biotech developing JSP191, an anti-CD117 antibody for conditioning prior to allogeneic hematopoietic stem cell transplant and gene therapy. Directly competes with Magenta's conditioning program in the same transplant-conditioning niche.
  • Actinium Pharmaceuticals: Develops Iomab-B and other targeted conditioning agents for hematopoietic stem cell transplantation. Targets the same transplant-conditioning indication as Magenta with a different modality (radioimmunotherapy).

Emerging players

  • Intellia Therapeutics: In vivo and ex vivo CRISPR-based gene editing company with HSC-adjacent programs. Shares the broader stem cell and gene therapy ecosystem in which Magenta's conditioning platform operates.
  • Allogene Therapeutics: Clinical-stage allogeneic CAR-T company using healthy donor T cells. Adjacent because allogeneic cell therapies intersect with the same donor, mobilization, and conditioning infrastructure Magenta targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Magenta Therapeutics social profiles

Digital presence

Magenta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Magenta Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Magenta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Magenta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Magenta Therapeutics

What does Magenta Therapeutics do?

Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics based on stem cell biology, with a focus on hematopoietic stem cell transplant conditioning and immune reset for patients with hematologic diseases and genetic disorders. The company advances biologic drug candidates intended for clinical use in transplant and immune-mediated disease settings.

Is Magenta Therapeutics a public or private company?

Magenta Therapeutics is a public company. It is classified as public and is currently operating.

When was Magenta Therapeutics founded?

Magenta Therapeutics was founded in 2016. It employs 1 to 10 people.

Where is Magenta Therapeutics based?

Magenta Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Magenta Therapeutics's main competitors?

Broad incumbents on record are Beam Therapeutics, Editas Medicine, Vertex Pharmaceuticals and CRISPR Therapeutics. Direct peers are bluebird bio, Vor Biopharma, Jasper Therapeutics and Actinium Pharmaceuticals. Emerging players are Intellia Therapeutics and Allogene Therapeutics.

Does Magenta Therapeutics have an API?

No public API is recorded for Magenta Therapeutics.

What industry is Magenta Therapeutics in?

Magenta Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial ResultsDianthus Therapeutics reported Q3 2023 net loss of $14.8 million and $189.9 million in cash, after completing its merger with Magenta Therapeutics and a $72 million financing. The company announced positive top-line Phase 1 data for DNTH103, a complement inhibitor, and plans to start Phase 2 trials for generalized Myasthenia Gravis in Q1 2024.DianthustxMagenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock SplitMagenta Therapeutics, Inc. announced the completion of its merger with Dianthus Therapeutics, Inc. on September 11, 2023. Following the merger, Magenta implemented a reverse stock split of 1-for-16 to comply with Nasdaq's minimum bid price requirement, and the combined company will operate as Dianthus Therapeutics, Inc., trading under the ticker symbol "DNTH" starting September 12, 2023.BenzingaMagenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient DeathMagenta Therapeutics Inc and privately-held Dianthus Therapeutics Inc have announced an all-stock merger, with the combined company to operate under Dianthus' name and trade on Nasdaq under the ticker DNTH. The merger follows Magenta's January pause and subsequent halt of its acute myeloid leukemia Phase 1/2 trial due to a patient death, which triggered an 84% workforce reduction and a search for strategic alternatives. The combined entity is expected to have approximately $180 million in cash to fund Dianthus' lead program DNTH103 through clinical trials in generalized Myasthenia Gravis and other indications into mid-2026.GlobeNewswireMagenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementMagenta Therapeutics and Dianthus Therapeutics announced a definitive merger agreement to combine in an all-stock transaction, with the combined company expected to trade on Nasdaq under "DNTH". The combined company is expected to have approximately $180 million in cash, including $70 million from a concurrent private financing, to fund operations into mid-2026. The merger is expected to close in the third quarter of 2023.DianthustxMagenta Therapeutics and Dianthus Therapeutics Announce Merger AgreementMagenta Therapeutics and Dianthus Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, with the resulting entity operating under the name Dianthus Therapeutics and trading on Nasdaq. The combined company is expected to hold approximately $180 million in cash upon closing, funded by existing assets and a concurrent $70 million private investment, which will support clinical development of its lead program DNTH103 through mid-2026. The transaction has been unanimously approved by both boards and is anticipated to close in the third quarter of 2023.American City Business JournalsMagenta Therapeutics to shut down after patient deathMagenta Therapeutics, a Cambridge biotech, will shut down after a patient death in a clinical trial. The company will become at least the 10th Massachusetts biotech to close since early 2022.PR NewswireThinking about buying stock in Genetic Technologies, Heart Test Laboratories, Magenta Therapeutics, Carvana, or C3.ai?InvestorsObserver issued PriceWatch Alerts for GENE, HSCS, MGTA, CVNA, and AI on Feb. 3, 2023. The alerts use a proprietary scoring system combining short-term and long-term technical and fundamental factors to rate each stock's investment suitability.GlobeNewswireMagenta Therapeutics to Explore Strategic AlternativesMagenta Therapeutics announced it has completed a review of its business and decided to halt further development of its programs. The company will explore strategic alternatives, including acquisition, merger, or business combination, to maximize shareholder value. No timetable was set for the review.The Pharma LetterAnother setback for Magenta Therapeutics' MGTA-117Magenta Therapeutics paused dosing in its MGTA-117 Phase I/II trial after a participant at the 0.08mg/kg Cohort 3 level died from respiratory failure and cardiac arrest, an event possibly related to the drug. The company reported the death to the FDA as a suspected unexpected serious adverse reaction and is evaluating next steps.GlobeNewswireMagenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug SafetyMagenta Therapeutics paused dosing in its MGTA-117 Phase 1/2 trial after a participant at Cohort 3 (0.08 mg/kg) experienced a Grade 5 SAE (respiratory failure and cardiac arrest leading to death) possibly related to the drug. The event was reported to the FDA as a SUSAR, and the company is evaluating data to determine next steps.